PreveCeutical Medical Inc.
PRVCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $10 | $10 | $5 |
| Gross Profit | $0 | -$10 | -$10 | -$5 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $92 | $78 | $172 |
| G&A Expenses | $306 | $425 | $309 | $658 |
| SG&A Expenses | $660 | $813 | $1,009 | $768 |
| Sales & Mktg Exp. | $142 | $101 | $75 | $110 |
| Other Operating Expenses | -$659 | $58 | $1 | -$42 |
| Operating Expenses | $1 | $963 | $1,088 | $898 |
| Operating Income | -$812 | -$963 | -$1,059 | -$898 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$362 | -$311 | -$423 | -$849 |
| Pre-Tax Income | -$1 | -$1,274 | -$1,481 | -$1,747 |
| Tax Expense | $0 | $0 | $0 | -$20 |
| Net Income | -$1,175 | -$1,274 | -$1,481 | -$1,727 |
| % Margin | – | – | – | – |
| EPS | -0.002 | -0.002 | -0.003 | -0.003 |
| % Growth | 8.3% | 14.3% | 17.6% | – |
| EPS Diluted | -0.002 | -0.002 | -0.003 | -0.003 |
| Weighted Avg Shares Out | 536,137 | 535,492 | 521,790 | 507,953 |
| Weighted Avg Shares Out Dil | 536,112 | 535,303 | 521,790 | 507,953 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $310 | $237 | $467 |
| Depreciation & Amortization | $0 | $10 | $10 | $5 |
| EBITDA | -$753 | -$905 | -$1,026 | -$830 |
| % Margin | – | – | – | – |